The CAP17 Abstract Program
CAP17 - THE Pathologists' Meeting
October 8-11, 2017
National Harbor, Maryland

<table>
<thead>
<tr>
<th>Important Dates to Remember:</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 9, 2017</td>
</tr>
<tr>
<td>March 10, 2017</td>
</tr>
<tr>
<td>May 24, 2017</td>
</tr>
<tr>
<td>August 11, 2017</td>
</tr>
</tbody>
</table>

Abstract and case study submissions are now being accepted; click on the link below to access the submission site:

http://bit.ly/2hiQ70z

Submissions will be accepted through 5 p.m. Central time Friday, March 10, 2017.

The CAP17 Abstract Program is a competitive program sponsored by the College of American Pathologists. The program is designed to promote a broad range of research in pathology. It offers pathologists and research scientists the opportunity to present original research to their peers in a poster presentation format. Editors from the Archives of Pathology & Laboratory Medicine will evaluate submissions to this program.

In addition, the CAP17 Abstract Program provides a unique opportunity for residents to enhance research skills, develop writing proficiency, gain practical experience at presenting their findings, and contribute to the literature and advancement of pathology. Accepted abstracts and case studies will be published as a Web-only supplement to the September 2017 issue of the Archives. CAP junior members who have their abstracts accepted are eligible to be selected as a Top 5 Junior Member Abstract Program award winner. The Top 5 junior member winners will also be considered for the CAP17 Platform Poster Session. See the text on page 5 for specific requirements and information about this program.

CAP17 Abstract Program Evaluation Criteria
Abstracts will be evaluated on the following criteria:

- Significance of the hypothesis
- Valid conclusion(s)
- Argument clarity
• Presentation quality

Case studies must include novel findings, such as the following:
• A new disease or condition (i.e. not previously reported).
• A distinctive or unusual presentation of a known disease, with one or more well-documented new findings of special clinical relevance (i.e., potentially applicable to diagnosis, therapy, prognosis, etc.) or that serves to provide new insight into the possible pathogenesis of a disease (hypothesis-generating). The new information might be derived from distinctive morphology and/or ancillary testing.
• A known disease with a demonstrated new finding using state-of-the-art techniques (immunohistochemical, molecular, 3-dimensional reconstruction, cytogenetics, etc.) relevant to a clearly stated hypothesis.
• A known disease presenting with a previously undescribed clinically or etiologically relevant association (i.e., a myelodysplastic syndrome associated with a plasma cell dyscrasia, etc.) in order to heighten awareness of a possible link between entities. Such a link might have been described before in one or more individual case reports, and the addition of a case might help solidify a real association.

Submission Categories
Abstracts and case studies may be submitted to the following categories:

Anatomic Pathology
Autopsy and forensic pathology
Bone and soft tissue pathology
Breast pathology
Cardiovascular pathology
Cytopathology
Dermatopathology
Endocrine pathology
Head, neck, and oral pathology
Ophthalmic pathology
Gastrointestinal and liver pathology
Gynecologic and placental pathology
Kidney and genitourinary pathology
Neuropathology
Pulmonary and mediastinal pathology

Clinical Pathology
Clinical chemistry
Clinical immunology
Hematopathology
Microbiology
Requirements for Submitting Abstracts/Case Studies

- All abstracts/case studies must be submitted by **5 p.m. Central time March 10, 2017**. Submissions received after this date will not be considered.
- Submissions may not have already been published or currently be under consideration for publication elsewhere.
- Abstracts/case studies must be submitted electronically via the submission site. A link to the submission site will be added to this text on January 9 (see above).
- Corresponding authors (the person who submits the abstract or case study) are responsible for submitting financial disclosure information for all authors. This information will be submitted directly into the submission site; paper authorship forms are not accepted. Corresponding authors should obtain any relevant financial disclosures and the e-mail addresses for all co-authors prior to starting the submission process.
- All steps in the submission process must be completed. Incomplete submissions, including those that exceed the word count limit, will not be considered. It is the corresponding author's responsibility to complete/revise incomplete submissions.

Specific text requirements:

- Text must be prepared in accordance with the American Medical Association Manual of Style, 10th edition. For specific examples of how submissions should be prepared, see the CAP16 abstracts and case studies that were published as a Web-only supplement to the September 2016 issue of the Archives at [www.archivesofpathology.org](http://www.archivesofpathology.org). Also see specific Table and Figure Requirements below.
- For abstracts, the body of the text may contain a maximum of 254 words and must be organized under (and contain) all of the following headings: Context, Design, Results, and Conclusions. Do not use any additional or alternative headings.
- A case study may include no more than 2 cases. The body of the text may contain a maximum of 250 words. It should not contain any headings.
- Do not use abbreviations unless they appear 5 or more times, in which case you must spell out the abbreviation the first time it appears.
- Do not begin the abstract or case study by repeating the title, and do not cite references; references will not be published in accepted abstracts.
- Affiliations for each author must be clearly listed, including full department and institution names. Spell out this information; do not use abbreviations or acronyms.
- List sources (name of company, city, state, and country) for all software and reagents.
- Use conventional units of measure.
- Use generic drug names unless the specific trade name of a drug is directly relevant to the discussion.
- Retrospective studies should be consistently written in the past tense.
- Perform a spell check of your submission prior to submitting it.
- A single table or figure may be added using the “Add Graphic” or “Add Table” button. Note: a single figure that contains up to 4 smaller figures (a “composite”) will be allowed. Figure composites that contain more than 4 figures will not be allowed.
- If submitting a figure or table, specifically refer to it (e.g., Table, Figure) in the text. Do not include a specific table or figure number (see requirements below) and do not submit a separate figure or table legend (caption); legends will not be printed.

**Table requirements:**
1. Tables must not contain more than 5 columns.
2. Acronyms used in a table must be clearly defined in a footnote.
3. Tables must have a descriptive title that concisely summarizes the content of the table.
4. Tables cannot be submitted as figure files (JPEG or PDF files).

**Figure requirements:**
1. Figure files must be submitted in JPEG format at a minimum resolution of 300 dpi.
2. If any text appears in a figure, it must be 12 points or larger.
3. Do not submit photomicrographs as either Word or PowerPoint files.
4. Do not add a figure label on single figures. If submitting a figure composite of 4 figures, add A, B, C, and D labels in the lower left-hand corner of the appropriate figure; **do not** include figure numbers. Figure composites must not contain more than 4 smaller figures.
5. Figures from accepted submissions will be published in the Archives at a width of 3 ½ inches. Thus, computer screen shots and other figures that contain small text are not good submission options. It is critical that you view your figures at a width of 3½ inches to determine whether all text is clearly legible. If the text is not legible, the figure should be remade.
Improperly prepared figures and tables will be returned to corresponding authors for revision.

Accepted submissions will be published as a Web-only supplement to the September 2017 issue of the Archives.

**CAP Top 5 Junior Member Abstract Program**
Authors of the top five accepted abstracts received from CAP junior members will be named as the Top 5 Junior Member Abstract Program award winners and given cash prizes:
- First place cash award = $1,500
- Second place cash award = $1,000
- Third place cash award = $750
- Fourth and fifth place cash awards are $500 each.

To be eligible for the CAP17 Top 5 Junior Member Abstract Program awards, a CAP junior member must:
1. Have performed a substantial portion of the research and work involved in the preparation of the abstract;
2. Be listed as either the first or second author;
3. Serve as the corresponding author.

Top 5 Junior Member Abstract Program award winners will be notified by August 11, 2017 and cash prizes will be awarded during the CAP17 meeting. The award winners will also be recognized during the CAP17 meeting and their winning posters will be prominently displayed at the meeting. In addition, the Top 5 winners will be considered for the Platform Poster Session.

**Author Requirements**
Corresponding authors must be available to respond to questions about the content of their submissions from the Archives editorial office, especially during the period of April 10 to May 10, 2017. E-mail addresses for corresponding authors must be active and accessible until at least August 2017. Corresponding authors will be notified of their submission status by May 24, 2017.

Authors of accepted submissions must prepare a 4’ x 8’ foot poster summary of their abstract/case study for presentation at CAP17. The poster must be displayed by the authors during CAP17, and the authors are expected to be present at their posters during specified Poster Focus times to discuss and answer questions about their research. Specific information regarding Poster Focus times and dates will be included in the acceptance notification e-mail sent to corresponding authors.

**CAP17 Registration**
All authors presenting posters are required to register for CAP17 and to pay the appropriate fees. Registration for CAP17 is expected to begin in May 2017.

Questions
If you have questions about the content of your abstract or case study, please e-mail contactcenter@cap.org prior to completing your submission. Your questions will be routed to the abstract program coordinator. Remember, submissions cannot be changed or resubmitted after the submission deadline.